Saccharomyces boulardii CNCM I-745 supplementation reduces gastrointestinal dysfunction in an animal model of IBS

Abstract

BackgroundWe evaluated the effect of Saccharomyces boulardii CNCM I-745 on intestinal neuromuscular anomalies in an IBS-type mouse model of gastrointestinal motor dysfunctions elicited by Herpes Simplex Virus type 1 (HSV-1) exposure.MethodsMice were inoculated intranasally with HSV-1 (102 PFU) or vehicle at time 0 and 4 weeks later by the intragastric (IG) route (108 PFU). Six weeks after IG inoculum, mice were randomly allocated to receive oral gavage with either S. boulardii (107 CFU/day) or vehicle. After 4 weeks the following were determined: a) intestinal motility using fluorescein-isothiocyanate dextran distribution in the gut, fecal pellet expulsion, stool water content, and distal colonic transit of glass beads; b) integrity of the enteric nervous system (ENS) by immunohistochemistry on ileal whole-mount preparations and western blot of protein lysates from ileal longitudinal muscle and myenteric plexus; c) isometric muscle tension with electric field and pharmacological (carbachol) stimulation of ileal segments; and d) intestinal inflammation by levels of tumor necrosis factor α, interleukin(IL)-1β, IL-10 and IL-4.ResultsS. boulardii CNCM I-745 improved HSV-1 induced intestinal dysmotility and alteration of intestinal transit observed ten weeks after IG inoculum of the virus. Also, the probiotic yeast ameliorated the structural alterations of the ENS induced by HSV-1 (i.e., reduced peripherin immunoreactivity and expression, increased glial S100β protein immunoreactivity and neuronal nitric oxide synthase level, reduced substance P-positive fibers). Moreover, S. boulardii CNCM I-745 diminished the production of HSV-1 associated pro-inflammatory cytokines in the myenteric plexus and increased levels of anti-inflammatory interleukins.ConclusionsS. boulardii CNCM I-745 ameliorated gastrointestinal neuromuscular anomalies in a mouse model of gut dysfunctions typically observed with irritable bowel syndrome.

Synergistic Effect of Berberine-Based Chinese Medicine Assembled Nanostructures on Diarrhea-Predominant Irritable Bowel Syndrome In Vivo

“…Correspondingly, we examined these BGPs level in colon and serum in our study. The reason why we chose to detect BGPs in serum instead of that in brain was that the change trend of BGPs both in colon and serum consistent with the psychiatric symptoms of IBS-D patients ( Holzer and Farzi, 2014 ; Brun et al, 2017 ), our preliminary experiments demonstrated that brain symptoms appeared such as depression, anxiety-like behaviors, and pain on IBS-D mice and the BGPs in serum was more suitable for dynamic observation than that in brain in a follow-up experiment. BGPs experimental results showed that BA-BBR NPs significantly reduced the levels of 5-HT, VIP, and CHAT in colon tissues or of serum compared with other drugs, indicating that the ameliorative synergistic action of BA-BBR NPs is attained by influencing BGPs.…”

“…After 1 week of acclimation, the IBS-D model was established by daily gavage of senna decoction (0.6 g/kg) plus restraint stress(for a duration of 1 h starting from 1 h after the gavage) for 2 weeks, as previously reported ( Sun et al, 2015 ; Brun et al, 2017 ; Zhu et al, 2019 ). The experimental scheme was approved by the Laboratory Animal Ethics Committee of Beijing University of Chinese Medicine.…”

Mycobiome in the Gut: A Multiperspective Review

“…Additionally, targeting gut mycobiota could be one of the potential intervention strategies to relieve neurological and neuropsychiatric disorders. For example, administration of Saccharomyces boulardii CNCM I-745 had improved intestinal neuromuscular anomalies in IBS-induced mouse model prior to Herpes Simplex Virus type 1 (HSV-1) exposure [167]. A recent study also documented the protective role of mycobiota in reducing inflammation in the central nervous system.…”

A Review of Microbiota and Irritable Bowel Syndrome: Future in Therapies

“…Moreover, some focused meta-analyses investigated the role of Saccharomyces boulardii [ 89 ] and B. infantis [ 90 ] in adults, Lactobacillus rhamnosus GG in children [ 91 ] and Lactobacillus species and strains in both children and adults [ 92 ] with IBS. S. boulardii induced a significant improvement of bowel frequency, but even this result was replicated in animal stress and viral infection models, and the mechanism is not known [ 93 , 94 ]. B. infantis alone did not have an impact on abdominal pain, bloating/distention or bowel habit satisfaction though patients who received composite probiotics containing B. infantis had significantly reduced abdominal pain (standardized mean difference (SMD), 0.22; 95% CI, 0.03–0.41) and bloating/distention (SMD, 0.30; 95% CI, 0.04–0.56).…”